David has 30 years’ experience in Health and Research finance.
With 30 years of experience in early phase research, particularly specialising in respiratory studies, Liz now a Director of MEU has held a Senior Management position at MEU since 2002.
Dave Singh is Professor of Respiratory Pharmacology at the University of Manchester.
David has 30 years’ experience in Health and Research finance.
In 1999 he joined the Medicines Evaluation Unit Ltd as Director of Operations and was instrumental in turning a grant-funded NHS department into a successful Phase I clinical trials unit. He also is a Director and co-founder of CRO-Solutions Ltd, a CRO offering clinical trials services to Pharma worldwide.
Previously he held senior finance roles in the NHS, in the areas of Contracting and Management Accounting. He is a member of the Medicines and Healthcare products Regulatory Agency (MHRA) phase 1 stakeholder committee and also helped develop the NHS clinical trials agreement the mCTA.
Liz qualified as a Registered Nurse in 1980 and began her career in respiratory medicine within secondary care, later transitioning into primary care where she built a solid foundation in patient-focused practice.
In 1995, Liz joined the Medicines Evaluation Unit (MEU), in the early years working as a Research Nurse followed by Project Management and Recruitment Manager. In these roles, she was responsible for the setup, conduct, and day-to-day management of clinical trials across a range of therapeutic areas.
With 30 years of experience in early phase research, particularly specialising in respiratory studies, Liz now a Director of MEU has held a Senior Management position at MEU since 2002. Her responsibilities include feasibility assessment of study protocols, strategic planning and oversight of trial delivery, and ensuring full compliance with regulatory requirements to uphold the MHRA Phase I Accreditation.
Liz’s extensive clinical and operational expertise continues to play a key role in MEU’s success as a leading early phase unit in the UK.
Dave Singh is Professor of Respiratory Pharmacology at the University of Manchester.
He graduated from Cambridge University and went on to train in medicine and clinical pharmacology in Manchester, which included working in industry on early phase clinical trials. His research interests are in the pharmacotherapy of Asthma and COPD, with studies spanning from basic pharmacology of anti-inflammatory drugs to clinical trials.
He has acted as Principal Investigator on numerous clinical trials of novel therapies in asthma and COPD, and has over 200 publications in peer reviewed journals. He is a member of the GOLD Science Committee.